Trial · NCT04042623

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

NCT04042623, Phase 2, Terminated, Aravive, Inc.; results first posted 2022-02-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy. Trials, record NCT04042623. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04042623

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
NCT number: NCT04042623
Status: Terminated
Phases: Phase 2
Enrollment: 1 participants, actual
Lead sponsor: Aravive, Inc.
Conditions: IgA Nephropathy
Interventions: AVB-S6-500
First posted: 2019-08-02
Last updated: 2022-02-10
Results first posted: 2022-02-10
Limitations and caveats: After enrollment of one subject, the study was paused due to the COVID-19 pandemic. Subsequently, the sponsor terminated the study due to a change in sponsor priorities.

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Incidence of Adverse Events (AEs)	14 weeks	Measured by the number of patients with AEs
Primary	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in 24-hour Urine Protein Excretion (UPE) in g/Day.	12 weeks
Primary	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in 24-hour Urine Protein Excretion (UPE) in g/Day in the Subset of Patients With Baseline High Proteinuria.	12 weeks
Primary	The Effect of AVB-S6-500 on Proportion of Patients With Urinary Protein Equivalent of < 1 g/24 Hours at End of Treatment	12 weeks
Primary	The Effect of AVB-S6-500 on Proportion of Patients Who Had at Least a Decrease of 0.5 g/Day Proteinuria From Baseline to End of Treatment.	12 weeks
Primary	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in Urine Albumin/Creatinine Ratios (uACRs).	12 weeks
Primary	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in Estimated Glomerular Filtration Rate (eGFR).	12 weeks
Secondary	Incidence of Anti-drug Antibody (ADA)	14 weeks	The number of participants with anti-AVB-S6-500 antibodies
Secondary	Titers of Anti-AVB-S6-500 Antibodies	14 weeks
Secondary	Apparent Terminal Half-life (t1/2) of AVB-S6-500	12 weeks

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Incidence of Adverse Events (AEs)	14 weeks		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in 24-hour Urine Protein Excretion (UPE) in g/Day.	12 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
PRIMARY	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in 24-hour Urine Protein Excretion (UPE) in g/Day in the Subset of Patients With Baseline High Proteinuria.	12 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
PRIMARY	The Effect of AVB-S6-500 on Proportion of Patients With Urinary Protein Equivalent of < 1 g/24 Hours at End of Treatment	12 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
PRIMARY	The Effect of AVB-S6-500 on Proportion of Patients Who Had at Least a Decrease of 0.5 g/Day Proteinuria From Baseline to End of Treatment.	12 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
PRIMARY	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in Urine Albumin/Creatinine Ratios (uACRs).	12 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
PRIMARY	The Effect of AVB-S6-500 on Change From Baseline to End of Treatment in Estimated Glomerular Filtration Rate (eGFR).	12 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
SECONDARY	Incidence of Anti-drug Antibody (ADA)	14 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
SECONDARY	Titers of Anti-AVB-S6-500 Antibodies	14 weeks	The subject discontinued the study before data were collected, hence the outcome measure was not analyzed.
SECONDARY	Apparent Terminal Half-life (t1/2) of AVB-S6-500	12 weeks	Samples were not analyzed because the study was terminated by the Sponsor.

1 to 10 of 13Source ClinicalTrials.gov

See all 13 outcomes

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Incidence of Adverse Events (AEs)	Treatment With AVB-S6-500		1		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment With AVB-S6-500	1
Overall Study	COMPLETED	Treatment With AVB-S6-500	0
Overall Study	NOT COMPLETED	Treatment With AVB-S6-500	1

Source ClinicalTrials.gov

Adverse events3

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Decreased blood pressure	Vascular disorders	Treatment With AVB-S6-500	1	1	1
other	Rigor	General disorders	Treatment With AVB-S6-500	1	1	1
other	Feeling heavy (heaviness) in the back	Musculoskeletal and connective tissue disorders	Treatment With AVB-S6-500	1	1	1

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment With AVB-S6-500	0	1
Total, other adverse events	Treatment With AVB-S6-500	1	1
Total, serious adverse events	Treatment With AVB-S6-500	0	1

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04042623

GET https://conductscience.org/api/trials/v1/NCT04042623/registered

API reference For AI assistants